Resource impact statement
No significant resource impact is anticipated
NICE has recommended apalutamide plus androgen deprivation therapy (ADT) as an option for treating hormone-sensitive metastatic prostate cancer in adults. It is recommended only if docetaxel is not suitable and the company provides apalutamide according to the commercial arrangement.
We do not expect this guidance to have a significant impact on resources; that is, the resource impact of implementing the recommendations in England will be less than £5 million per year in England (or approximately £9,000 per 100,000 population, based on a population for England of 56.3 million people).
This is because the technology is a further treatment option which is available at a similar price to current treatment options.
Apalutamide has a discount that is commercial in confidence. It is the company’s responsibility to let relevant NHS organisations know details of the discount.
This technology is commissioned by NHS England. Providers are NHS hospital trusts.
This page was last updated: